Janus Henderson Group PLC Akero Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $188 Billion
- Q4 2024
A detailed history of Janus Henderson Group PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 6,034,239 shares of AKRO stock, worth $258 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
6,034,239
Previous 7,077,478
14.74%
Holding current value
$258 Million
Previous $203 Million
17.33%
% of portfolio
0.09%
Previous 0.11%
Shares
23 transactions
Others Institutions Holding AKRO
# of Institutions
209Shares Held
66.9MCall Options Held
321KPut Options Held
558K-
Rtw Investments, LP New York, NY6.86MShares$293 Million3.11% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$239 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$224 Million5.21% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$185 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.7MShares$158 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.98B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...